Answers are grounded in this paper and cite their sources.
Engineered cytochrome P450 monooxygenase variants are reported as highly active and selective catalysts for the bioorthogonal uncaging of propargylic and benzylic ether protected substrates, including uncaging in living E. coli. observed selectivity is supported by induced-fit docking and molecular dynamics simulations. This proof-of-principle study points towards the utility of bioorthogonal enzyme/protecting group pairs for applications in the life sciences.
No takes yet. Share an insight, caveat, or question.
Ritter et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: